润肺固肾汤联合吡非尼酮片、醋酸泼尼松片治疗进展性肺纤维化(肺肾气阴两虚证)的疗效观察  

Efficacy of Runfei Gushen Decoction Combined with Pirfenidone Tablets and Prednisone Acetate Tablets in the Treatment of Progressive Pulmonary Fibrosis(Qi and Yin Deficiency of Lung and Kidney Syndrome)

作　　者：焦晨雪 刘建伟[1] 张云云 曹洁 徐娜 JIAO Chenxue;LIU Jianwei;ZHANG Yunyun;CAO Jie;XU Na(Dept.of Respiratory,Handan Hospital of Traditional Chinese Medicine Hospital,Hebei Handan 056001,China)

机构地区：[1]邯郸市中医院呼吸科,河北邯郸056001

出　　处：《中国医院用药评价与分析》2024年第6期693-696,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：河北省中医药管理局科研计划项目(No.2024521)。

摘　　要：目的:探讨润肺固肾汤联合吡非尼酮片、醋酸泼尼松片治疗进展性肺纤维化(肺肾气阴两虚证)的疗效。方法:选取2021年2月至2023年6月该院收治的进展性肺纤维化(肺肾气阴两虚证)患者120例,采用随机数字表法分为观察组(n=60)和对照组(n=60)。对照组患者实施吡非尼酮片+醋酸泼尼松片治疗,观察组患者在对照组的基础上联合润肺固肾汤治疗,均持续治疗12周。比较两组患者治疗前后高分辨率CT(HRCT)影像学评分、运动耐力[6 min步行试验距离(6MWD)]、生活质量[圣乔治呼吸问卷(SGRQ)评分]、肺功能[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)及最大呼气流量(MEF)]和纤维化指标[血清涎液化糖链抗原-6(KL-6)]水平;评估临床疗效、用药安全性。结果:观察组患者的总有效率为95.00%(57/60),较对照组的81.67%(49/60)更高,差异有统计学意义(P<0.05)。治疗后,两组患者HRCT影像学评分、SGRQ评分和血清KL-6水平较治疗前显著降低,6MWD、FEV_(1)、FVC和MEF水平较治疗前显著升高;观察组患者HRCT影像学评分、SGRQ评分和血清KL-6水平较对照组更低,6MWD、FEV_(1)、FVC和MEF水平较对照组更高,差异均有统计学意义(P<0.05)。对照组、观察组患者的不良反应总发生率分别为8.33%(5/60)、10.00%(6/60),差异无统计学意义(P>0.05)。结论:润肺固肾汤联合吡非尼酮片、醋酸泼尼松片可有效缓解进展性肺纤维化(肺肾气阴两虚证)患者的临床症状和肺纤维化程度,改善运动耐力和生活质量,提高肺功能及临床疗效,安全性好。OBJECTIVE:To probe into the efficacy of Runfei Gushen decoction combined with Pirfenidone tablets and Prednisone acetate tablets in the treatment of progressive pulmonary fibrosis(Qi and Yin Deficiency of Lung and Kidney Syndrome).METHODS:A total of 120 patients with progressive pulmonary fibrosis(Qi and Yin Deficiency of Lung and Kidney Syndrome)admitted into the hospital from Feb.2021 to Jun.2023 were selected to be divided into observation group(n=60)and control group(n=60)via random number table method.The control group was given Pirfenidone tablets and Prednisone acetate tablets,while the observation group was given Runfei Gushen decoction based on the control group,both groups were treated for 12 weeks.The imaging scores of high-resolution CT(HRCT),exercise tolerance(6MWD),quality of life[St George’s Respiratory Questionnaire(SGRQ)score],pulmonary function[forced expiratory volume in first 1s(FEV_(1)),force vital capacity(FVC)and maximal expiratory flow(MEF)]and fibrosis indicators[serum Krebs Von den lungen-6(KL-6)]levels were compared between two groups before and after treatment;the clinical efficacy and medication safety were evaluated.RESULTS:The total effective rate of the observation group was 95.00%(57/60),higher than 81.67%(49/60)of the control group,with statistically significant difference(P<0.05).After treatment,the HRCT imaging scores,SGRQ scores and serum KL-6 levels of both groups were significantly lower than those before treatment,the 6MWD,FEV_(1),FVC and MEF of both groups were significantly higher than those before treatment;the HRCT imaging score,SGRQ score and serum KL-6 level of the observation group were lower than those of the control group,the 6MWD,FEV_(1),FVC and MEF of the observation group were higher than those of the control group,with statistically significant differences(P<0.05).The total incidences of adverse drug reactions of the control group and the observation group were respectively 8.33%(5/60)and 10.00%(6/60),the difference was not statistically significant(P>0.05).C

关 键 词：润肺固肾汤 吡非尼酮片 醋酸泼尼松片 肺肾气阴两虚证 进展性肺纤维化 疗效 

分 类 号：R932[医药卫生—生药学] R974[医药卫生—药学] R977.1